Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib in active systemic lupus erythematosus
NCT05617677Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Deucravacitinib with Placebo (2 arms). Primary endpoint: Systemic Lupus Erythematosus Responder Index-4 at 52 weeks. Started Jan 2023; status: active, not recruiting.
02
Drugs
deucravacitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05617677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05617677.